KEY POINTS
- The study interrogated mutant IDH1R132H gliomas with TP53 and ATRX loss using multiple genetically engineered mouse models, human glioma cultures, RNA-seq, single-cell RNA-seq, ChIP/CUT&RUN and metabolomic analyses.
- IDH1-mutant glioma cells showed suppressed mitochondrial respiration and glycolysis together with increased expression of autophagy-related pathways, including ATG7, ATG9B, ULK1 and UVRAG, suggesting greater dependence on autophagy for energetic homeostasis.
- Molecular suppression of several autophagy components—including ATG7, ATG4B and ATG9B—significantly enhanced radiation-induced loss of viability in both mouse and human mutant-IDH1 glioma models, with several comparisons reaching p<0.0001.
- Importantly, blocking autophagy alone was not beneficial: genetically reducing ATG7 shortened median mouse survival from 154 to 120 days (p<0.001), suggesting autophagy suppression in isolation may actually promote more aggressive tumor behavior.
- Therapeutically, investigators delivered ATG7-targeting siRNA in synthetic protein nanoparticles together with 2 Gy/day radiation. Median survival was 60 days with the combination versus 37 days with RT alone, 35 days with empty nanoparticles, 33 days with saline and 26 days with ATG7i-SPNP alone.
- 40% of combination-treated mice survived tumor-free beyond 90 days. Long-term survivors rechallenged with mutant-IDH1 tumor cells in the contralateral hemisphere remained tumor-free without further therapy, whereas control mice died with median survival of 33 days.
- Combination treatment also increased tumor-antigen-specific CD8 T-cell proliferation, while no overt systemic toxicity, liver/kidney dysfunction or major histopathologic abnormalities were identified in treated animals.
CLINICAL TAKEAWAY
Autophagy appears to function as a radiation-stress survival pathway in IDH1-mutant glioma, making it an attractive radiosensitization target. The interaction is biologically complex—autophagy inhibition alone worsened tumor behavior—and the nanoparticle/ATG7 strategy remains far from clinical application, but the in-vivo radiation synergy is striking.